Single Cell Genomics In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Single-cell genomics encompasses a suite of high-throughput technologies that profile the transcriptome, epigenome, proteome, or multi-omic state of individual cells, enabling unprecedented resolution into the cellular heterogeneity that underlies [neurodegenerative ]. The human brain contains hundreds of distinct cell types — [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- platforms such as 10x Genomics Chromium, single-cell studies have generated comprehensive atlases of the healthy and diseased brain. In the context of [neurodegenerative ], these technologies have identified [disease-associated [microglia (DAM, revealed selective neuronal vulnerability patterns, uncovered novel [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- reactive states, mapped oligodendrocytes lineage disruption, and defined cell-type-specific transcriptional programs altered in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, and [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- (Mathys et al., 2019).
scRNA-seq captures the full transcriptional state of individual cells through:
Droplet-based platforms (10x Chromium) typically capture 3'-end transcripts from 5,000-20,000 cells per run at moderate depth (~2,000-5,000 genes per cell), while plate-based methods (SMART-seq2) provide full-length transcript coverage at higher depth from fewer cells, enabling isoform and splicing analysis.
For brain tissue, single-nucleus RNA sequencing (snRNA-seq) is often preferred because:
The trade-off is reduced sensitivity (nuclear transcriptomes capture ~50-70% of the genes detected in whole-cell preparations) and loss of cytoplasmic RNA species, including mitochondrial transcripts relevant to [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX-- research (Bakken et al., 2018).
scATAC-seq profiles chromatin accessibility at single-cell resolution, revealing:
This is particularly relevant for understanding how genetic risk variants for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- — the majority of which fall in non-coding regulatory regions — exert their effects in specific cell types (Corces et al., 2020.
Cutting-edge multi-omic methods simultaneously measure multiple modalities from the same cell:
These integrated approaches are especially powerful for dissecting the multi-layered molecular changes occurring in neurodegenerative disease cells.
One of the most impactful discoveries from single-cell genomics in neurodegeneration was the identification of [disease-associated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- (DAM — a unique [microglial state found in the vicinity of [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- plaques in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- mouse models and human brain tissue. DAM are characterized by upregulation of [TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX--, ApoE, Lpl, and phagocytic genes, with downregulation of homeostatic microglial markers (P2RY12, TMEM119, CX3CR1. [This discovery established that [microglia specific disease-response programs rather than simply being "activated" or "resting" (Keren-Shaul et al., 2017.
Subsequent studies identified additional microglial states including interferon-responsive [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia.
scRNA-seq revealed that [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- in [neurodegeneration] adopt multiple reactive states beyond the classical A1/A2 dichotomy, including disease-associated [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- (DAA) characterized by [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- upregulation, loss of homeostatic functions, and gain of inflammatory and complement signaling. These states differ across brain regions and disease stages.
Studies in [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- revealed disruption of oligodendrocytes maturation trajectories, with accumulation of disease-specific intermediate states that fail to fully myelinate or support axons, contributing to [demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination--TEMP--/mechanisms)--FIX-- and white matter degeneration.
Single-cell profiling of cerebrospinal fluid (CSF) and peripheral blood from patients with neurodegenerative diseases has identified disease-associated immune cell populations — including expanded clonal T cells, activated monocyte subsets, and aberrant B cell populations — providing liquid biopsy biomarkers and insights into [peripheral immune infiltration[/mechanisms/[peripheral-immune-infiltration[/mechanisms/[peripheral-immune-infiltration[/mechanisms/[peripheral-immune-infiltration--TEMP--/mechanisms)--FIX-- in neurodegeneration.
Standard analysis pipelines employ:
Automated annotation tools (CellTypist, scArches, Azimuth) map query datasets to reference brain cell atlases, enabling consistent cell type labeling across studies. The Allen Brain Cell Atlas and the Human Cell Atlas Brain initiative provide comprehensive reference datasets.
Pseudotime analysis and RNA velocity (scVelo) infer cell state transitions and differentiation trajectories from snapshot data, revealing how cells transition from healthy to disease states — for example, tracking [microglial transition or oligodendrocytes progenitor-to-myelinating cell trajectories.
Methods such as Harmony, scVI, and SCVI-tools enable integration of datasets across studies, laboratories, and technologies, building comprehensive meta-atlases that increase statistical power for detecting rare cell states and subtle disease effects.
Integration of scRNA-seq/scATAC-seq with genome-wide association study (GWAS data using tools like LDSC-SEG, scDRS, and SEISMIC enables cell-type-specific interpretation of genetic risk for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and other neurodegenerative conditions, identifying which cell types mediate genetic risk.
Key databases for single-cell neurodegeneration research include:
Single-cell genomics data are being translated into:
The study of Single Cell Genomics In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.